Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Hepregen Launches First Human HepatoPac™ Assay Kit

Published: Wednesday, March 26, 2014
Last Updated: Wednesday, March 26, 2014
Bookmark and Share
Application-directed kit provides information useful in predicting potential drug-induced liver injury.

At the Society of Toxicology's 53rd Annual Meeting, Hepregen Corporation has announced the commercial launch of the company's first HepatoPacT kit designed specifically for toxicology applications.

The kit contains one or more standard 96-well tissue culture plates featuring specially configured micro-patterned human liver cells co-cultured with stromal cells.

The liver cells (hepatocytes) on these plates mirror the behavior of liver cells in the body, enabling scientists to generate data that can be useful for prediction of toxic responses to chemical agents, including drug candidates.

The application-directed platform also provides a tool for the study of the mechanisms leading to such responses.

Jack McGeehan, Hepregen's Vice President of Operations, stated, "The hepatocytes in this specially configured product remain viable for weeks at a time, and they exhibit full functionality during this extended time period. This longevity means that the product may be useful for the study of chronic exposure to drug candidates and other new chemical entities, reflecting what likely could occur when humans are exposed to such agents for long periods. Because the hepatocytes also are fully active metabolically, investigators can evaluate toxicity associated with metabolites of these chemical entities in a single experiment."

Dr. Vincent Zurawski, Hepregen's Chief Executive Officer, stated, "This new kit is the first version of a human HepatoPacT application-directed kit that is focused on the in vitro toxicology market. In the coming months, aiming to serve this growing market, Hepregen also expects to be introducing more advanced HepatoPacT toxicology products, some of which are currently in development. The launch adds another product to the company's portfolio, which includes human, rat, monkey, human triple-donor and rat-human HepatoPacT application-directed kits for metabolite identification and profiling, and a recently introduced human kit to evaluate metabolic stability."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

QTS and Hepregen Execute Co-Development and Co-Marketing Agreement
Agreement provides for development, manufacture and sale of HepatoPac® B-CLEAR® co-labeled proprietary products for liver transporter analysis.
Tuesday, November 04, 2014
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos